Patent ID: 11970583
Assignee: STARPHARMA PTY LTD.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 0:
1. A method of treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of a dendrimer comprising:
i) a core unit (C), wherein the core unit is:, , and
ii) building units (BU), wherein the building unit are each:, wherein the acyl group of each building unit provides a covalent attachment point for attachment to the core or to a previous generation building unit and wherein each nitrogen atom provides a covalent attachment point for covalent attachment to a subsequent generation building unit, a first terminal group or a second terminal group;
wherein the core unit is covalently attached to two building units via amide linkages, each amide linkage being formed between a nitrogen atom present in the core unit and the carbon atom of an acyl group present in a building unit;
the dendrimer being a five generation building unit dendrimer;
wherein building units of different generations are covalently attached to one another via amide linkages formed between a nitrogen atom present in one building unit and the carbon atom of an acyl group present in another building unit;
the dendrimer further comprising:

iii) a plurality of first terminal groups (T1) each comprising a cabazitazel residue covalently attached to a diglycolyl linker group; and
iv) a plurality of second terminal groups (T2) each comprising a PEG group having an average molecular weight in the range of from 1,000 to 2,500 Daltons;
wherein at least one third of the nitrogen atoms present in outer building units are each covalently attached to a first terminal group; and
at least one third of the nitrogen atoms present in outer building units are each covalently attached to a second terminal group;
or a pharmaceutically acceptable salt thereof.